Literature DB >> 7418964

Hyperglucagonaemia in cirrhosis. Relationship to hepatocellular damage.

G Smith-Laing, H Orskov, M B Gore, S Sherlock.   

Abstract

Plasma glucagon and growth hormone concentrations were measured fasting and after oral glucose in 19 patients with portal vein block with extensive portal-systemic shunting but minimal liver cell damage, 11 cirrhotic patients and 12 matched control subjects. Portal vein block patients and controls had similar fasting glucose and glucagon levels (glucose 3.8 +/- 0.1 mmol/l VS control 3.4 +/- 0.1 mmol/l (mean +/- SEM); glucagon 57.5 +/- 9.1 pg/ml VS control 51.3 +/- 7.8 pg/ml). Cirrhotic patients were hyperglycaemic (cirrhosis 4.3 +/- 0.2 mmol/l VS control 3.4 +/- 0.1 mmol/l, p < 0.01) with significantly elevated glucagon levels (167.3 +/- 61.1 pg/ml VS control 51.3 +/- 7.8 pg/ml, p < 0.05), which suppressed towards control values after oral glucose. There was no correlation between fasting plasma glucagon levels and the degree of portal-systemic shunting in cirrhotic patients. There was a strong correlation between fasting plasma glucagon concentrations and aspartate transaminase levels (r = 0.68; p < 0.01) in cirrhotic and portal vein block patients. Significant elevations of growth hormone were seen only in cirrhotic patients. It is concluded that hyperglucagonaemia is a feature of hepatocellular damage rather than portal-systemic shunting but the relationship between elevated glucagon and growth hormone concentrations and carbohydrate intolerance in cirrhosis remains unclear.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7418964     DOI: 10.1007/bf00421854

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  31 in total

1.  BLOOD AMMONIA DURING BLEEDING FROM ESOPHAGEAL VARICES IN PATIENTS WITH HEPATOSPLENIC SCHISTOSOMIASIS.

Authors:  K S WARREN; G REBOUCAS
Journal:  N Engl J Med       Date:  1964-10-29       Impact factor: 91.245

2.  Insulin, glucagon, portal systemic shunting, and hepatic failure in the dog.

Authors:  P B Soeters; G Weir; A M Ebeid; J E Fischer
Journal:  J Surg Res       Date:  1977-09       Impact factor: 2.192

3.  Behavior of pancreatic glucagon, insulin, and HGH in liver cirrhosis, after arginine and I.V. glucose.

Authors:  A V Greco; G Ghirlanda; C Patrono; G Fedili; R Manna
Journal:  Acta Diabetol Lat       Date:  1974 Jul-Aug

4.  Portal and peripheral vein immunoreactive glucagon concentrations after arginine or glucose infusions.

Authors:  W G Blackard; N C Nelson; S S Andrews
Journal:  Diabetes       Date:  1974-03       Impact factor: 9.461

5.  A controlled study of the prophylactic portacaval shunt. A final report.

Authors:  R H Resnick; T C Chalmers; A M Ishihara; A J Garceau; A D Callow; E M Schimmel; E T O'Hara
Journal:  Ann Intern Med       Date:  1969-04       Impact factor: 25.391

6.  Decreased insulin production, elevated growth hormone levels, and glucose intolerance in liver disease.

Authors:  A Hernandez; E Zorrilla; H Gershberg
Journal:  J Lab Clin Med       Date:  1969-01

7.  Grey-scale ultrasonography of portal vein.

Authors:  L J Webb; L A Berger; S Sherlock
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

8.  Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs.

Authors:  T E Starzl; K Watanabe; K A Porter; C W Putnam
Journal:  Lancet       Date:  1976-04-17       Impact factor: 79.321

9.  Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon.

Authors:  R S Sherwin; M Fisher; J Bessoff; N Snyder; R Hendler; H O Conn; P Felig
Journal:  Gastroenterology       Date:  1978-06       Impact factor: 22.682

10.  Hyperinsulinism of hepatic cirrhosis: Diminished degradation or hypersecretion?

Authors:  D G Johnson; K G Alberti; O K Faber; C Binder
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

View more
  6 in total

1.  Effects of octreotide on intestinal transit and bacterial translocation in conscious rats with portal hypertension and liver fibrosis.

Authors:  N Veal; H Auduberteau; C Lemarie; F Oberti; P Calès
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

2.  The presence of glucagon in ascitic fluid in cirrhotic patients.

Authors:  U M Kabadi; M S Uddinn; A B Eisenstein
Journal:  J Endocrinol Invest       Date:  1983-06       Impact factor: 4.256

3.  Insulin, C-peptide and glucagon levels during OGTT in hepatic cirrhosis and in patients with prehepatic block.

Authors:  L Gerö; L Korányi; F Szalay; B Büki; G Tamás
Journal:  Acta Diabetol Lat       Date:  1982 Jan-Mar

4.  Insulin and glucagon production in experimental cirrhosis.

Authors:  A Alwmark; A Santos; V Mamlok; G H Greeley; J C Thompson
Journal:  Ann Surg       Date:  1987-01       Impact factor: 12.969

5.  Changes in immunoreactive insulin, C-peptide immunoreactivity, and immunoreactive glucagon in acute viral hepatitis.

Authors:  K Kaneko; M Arai; H Funatomi; Y Hatta; K Mitamura
Journal:  J Gastroenterol       Date:  1995-10       Impact factor: 7.527

6.  Thyroid and Hepatic Haemodynamic Alterations among Egyptian Children with Liver Cirrhosis.

Authors:  Zeinab A El-Kabbany; Rasha T Hamza; Ahmed S Abd El Hakim; Lamis M Tawfik
Journal:  ISRN Gastroenterol       Date:  2012-07-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.